I hardly recognize the 340B drug discount program when I read the pharmaceutical industry’s criticisms about it. They say that 340B has grown too big, is without oversight and transparency, and is in desperate need of reform.
Trending:
An insider's view of the myths and misconceptions behind 340B 'reform'